Targeted therapy combo aims to improve survival in older leukemia patients
NCT ID NCT03249870
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive the drug during the first two treatment cycles only, followed by standard chemotherapy. The main goal is to see how many patients are alive after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inotuzumab ozogamicin
What this could lead to
If successful, this combination could offer a more effective and less toxic treatment option for older adults with this leukemia, potentially improving survival rates.
What could go wrong
This is a phase 2 study, so results are preliminary. The drug may cause side effects like liver toxicity or infections, and the benefit may not be confirmed in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PHILADELPHIA CHROMOSOME (PH)-NEGATIVE CD22+ B-CELL PRECURSOR (BCP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Amiens sud
Amiens, France
-
CH Lyon Sud
Pierre-Bénite, France
-
CH Meaux
Meaux, France
-
CH Montpellier
Montpellier, France
-
CH Reims
Reims, France
-
CH Rene Dubois
Cergy-Pontoise, France
-
CH Roubaix
Roubaix, France
-
CH Valenciennes
Valenciennes, France
-
CH Versailles
Le Chesnay, France
-
CH Victor Dupouy
Argenteuil, France
-
CH cote basque
Bayonne, France
-
CH metropole Savoie_ chambery
Chambéry, France
-
CHR Orléans
Orléans, France
-
CHRU Nancy
Vandœuvre-lès-Nancy, France
-
CHU Angers
Angers, France
-
CHU Besançon
Besançon, France
-
CHU Caen
Caen, France
-
CHU Clermond Ferrand
Clermont-Ferrand, France
-
CHU Grenoble
Grenoble, France
-
CHU Haut Leveque
Pessac, France
-
CHU Limoges
Limoges, France
-
CHU Nantes
Nantes, France
-
CHU Nice
Nice, France
-
CHU Nimes
Nîmes, France
-
CHU Pontchaillou
Rennes, France
-
CHU Strasbourg
Strasbourg, France
-
CHU la Reunion
La Réunion, France
-
Centre H Becquerel Rouen
Rouen, France
-
Centre Lacassagne
Nice, France
-
Centre Leon Berard
Lyon, France
-
HIA Percy
Clamart, France
-
Hopital Avicenne
Bobigny, France
-
Hopital Dijon
Dijon, France
-
Hopital Duchenne
Boulogne-sur-Mer, France
-
Hopital Mondor
Créteil, France
-
Hopital Necker
Paris, France
-
Hopital St Antoine
Paris, France
-
Hopital St Louis
Paris, France
-
IPC
Marseille, France
-
IUCT Oncopole
Toulouse, France
-
Institut de cancerologie
Saint-Priest-en-Jarez, France